Gilead’s HIV Dominance Drives Growth, but Diversification Risks Merits Scrutiny

Gilead (GILD) reported robust Q2 2026 results with $7.8 billion revenue, up 10% YoY, led by HIV franchise growth including Biktarvy and newly launched Yeztugo. The company raised its full-year sales outlook.

HIV products accounted for 75% of Q2 sales, with Yeztugo achieving $232M in revenue—770% higher than the prior year—suggesting potential for expanded prevention applications. Descovy grew 48% to $967M, and Biktarvy rose 7% to $3.8B, demonstrating sustained franchise strength.

Bull Case

Liver disease portfolio grew 10% to $877M, driven by Livdelzi adoption and chronic hepatitis B products. This diversification reduces reliance on HIV while maintaining growth across therapeutic areas.

Bear Case

HIV’s 75% market share creates vulnerability to competition or market shifts. Cell-therapy sales fell 14% to $417M, highlighting ongoing oncology challenges. Additionally, $11.2BN R&D losses from Acellx, Tubulis, and Ouro Medicines acquisitions underscore execution risks beyond HIV.

Hedge Fund Activity

Institutional ownership rose from 71 to 77 funds Q1 2026, indicating cautiously positive sentiment without definitive conviction shifts.

Conclusion

Gilead’s growth, particularly in HIV and liver disease, supports near-term strength. However, long-term success requires proving diversification beyond HIV, as current oncology initiatives have not yet delivered consistent results.

Source link